ACURA PHARMACEUTICALS, INC: debt financing — Acura's debt to related party grows to $10.3M; warns of possible shutdown without new financing by May-end

ACURA PHARMACEUTICALS, INC

Received four $100,000 loans from Abuse Deterrent Pharma on March 30, April 3, April 20, May 5, 2026, bringing principal to $10,294,279.
Accrued interest ~$1,090,000 as of May 5; interest rate 5.25% (7.5% on default).
Without additional financing by end of May 2026, company will need to scale back operations, furlough employees, or seek bankruptcy.
AD Pharma, which owns ~65% of Acura's common stock, is controlled by Mr. Schutte, who also owns ~13% directly.

item 1.01 item 2.01 item 2.03 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

ACURA PHARMACEUTICALS, INC incurred loan of $100,000 with Abuse Deterrent Pharma, LLC at 5.25%.

Instrument: loan
Principal: $100,000
Counterparty: Abuse Deterrent Pharma, LLC
Rate: 5.25%
Event: incurrence

Exact text from the filing

On each of March 30, 2026, April 3, 2026, April 20, 2026 and May 5, 2026, we received loans of $100,000 from Abuse Deterrent Pharma, LLC (“AD Pharma”).

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001104659-26-056748

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.